Rimonabant License Has Changed, UK
Main Category: DiabetesAlso Included In: Depression; Pharma Industry / Biotech Industry; Pharmacy / Pharmacist
Article Date: 03 Oct 2007 - 8:00 PDT
| Patient / Public: | ![]() |
4 (1 votes) |
| Healthcare Prof: | ![]() |
The license for weight control drug Rimonabant, taken by some people with Type 2 diabetes, has changed.
If you have a history of depression, are taking or have in the past taken anti-depressants, you should not be on Rimonabant as it can cause severe complications. In these cases, seek medical advice immediately.
In addition, if you develop symptoms of depression after taking Rimonabant, you should contact a healthcare professional straightaway.
If you would like further information about Rimonbant, please call sanofi-aventis on 01483 505 515.
http://www.diabetes.org.uk
Visit our diabetes section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/84465.php>
APA
http://www.medicalnewstoday.com/releases/84465.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





